Compass Therapeutics Provides Corporate Update [Yahoo! Finance]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Yahoo! Finance
study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), a previously reported third response has now been confirmed in a patient with Hodgkin Lymphoma (HL). CTX-8371 has demonstrated responses in patients with both solid tumor and hematologic malignancies, and the Company is now investigating potential accelerated pathways to approval for the treatment of both adult and pediatric patients with HL in the post-checkpoint inhibitor setting. Also in the CTX-8371 Phase 1 study, the previously disclosed deep partial response in a patient with triple negative breast cancer (TNBC) is now durable through week 32. Based on this and the other responses observed in the Phase 1 study, the CTX-8371 cohort expansions are now open for enrollment in patients with TNBC and non-small cell lung cancer (NSCLC). Initiation of a Phase 1 study of CTX-10726 (P
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics (NASDAQ:CMPX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.MarketBeat
- Compass Therapeutics Provides Corporate UpdateGlobeNewswire
CMPX
Earnings
- 8/11/25 - Miss
CMPX
Sec Filings
- 1/12/26 - Form 4
- 1/8/26 - Form EFFECT
- 1/6/26 - Form 8-K
- CMPX's page on the SEC website